Follow us on Twitter (@IHD_EPITRAN) and LinkedIN (IHD-EPITRAN group).
Comprehensive insight into epitranscriptomics of cardiovascular disease. Review of m6A and A-to-I modifications in cardiovascular diseases published in Molecular Therapy Nucleic Acids.
Full citation: Sikorski V, Vento A, Kankuri E; IHD-EPITRAN Consortium. Emerging roles of the RNA modifications N6-methyladenosine and adenosine-to-inosine in cardiovascular diseases. Mol Ther Nucleic Acids. 2022 Jul 20;29:426-461. doi: 10.1016/j.omtn.2022.07.018. PMID: 35991314; PMCID: PMC9366019.
IHD-EPITRAN study outline and aims. MD Vilbert Sikorski presented the IHD-EPITRAN study outline and aims at the American Heart Association Scientific Sessions 2021 as an ePOSTER on 13.11.2021. Click here to watch the presentation video or download the presentation slides.
IHD-EPITRAN study protocol. Epitranscriptomics of Ischemic Heart Disease—The IHD-EPITRAN Study Design and Objectives. Study protocol published in International Journal of Molecular Sciences.
Full citation: Sikorski V, Karjalainen P, Blokhina D, Oksaharju K, Khan J, Katayama S, Rajala H, Suihko S, Tuohinen S, Teittinen K, Nummi A, Nykänen A, Eskin A, Stark C, Biancari F, Kiss J, Simpanen J, Ropponen J, Lemström K, Savinainen K, Lalowski M, Kaarne M, Jormalainen M, Elomaa O, Koivisto P, Raivio P, Bäckström P, Dahlbacka S, Syrjälä S, Vainikka T, Vähäsilta T, Tuncbag N, Karelson M, Mervaala E, Juvonen T, Laine M, Laurikka J, Vento A, Kankuri E. Epitranscriptomics of Ischemic Heart Disease-The IHD-EPITRAN Study Design and Objectives. Int J Mol Sci. 2021 Jun 21;22(12):6630. doi: 10.3390/ijms22126630. PMID: 34205699; PMCID: PMC8235045.
ClinicalTrials.gov study registration. Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN) https://clinicaltrials.gov/ct2/show/NCT04533282